Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKDCT086 in Claudin18.2 Positive Advanced Solid Tumors
NCT05952375Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XKDCT086 in gastric cancer (GC), esophageal cancer and gastroesophageal junction adenocarcinoma, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Adverse Events at 12 months. Status: unknown.
02
Drugs
XKDCT086
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05952375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952375.